Onconetix (ONCO) Deferred Taxes (2024)

Onconetix (ONCO) posted quarterly Deferred Taxes of -$917998.0 for Q4 2024, down 1528.12% quarter-over-quarter from -$56384.0 in Q3 2024.

Onconetix (ONCO) Deferred Taxes (2024) Analysis & Trends

Onconetix (ONCO) has reported Deferred Taxes for 1 consecutive years, with -$917998.0 the latest figure, recorded in Q4 2024.

In Q4 2024, Deferred Taxes changed N/A year-over-year to -$917998.0; the TTM figure through Dec 2024 stood at -$1.0 million (changed N/A YoY), while the FY2024 annual figure was -$1.0 million, down 8199.7% from the prior year.
Deferred Taxes fell to -$917998.0 in Q4 2024 per ONCO's latest filing, from -$56384.0 in the prior quarter.
Across five years, Deferred Taxes topped out at $50768.0 in Q2 2024 and bottomed at -$917998.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	2.66 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Onconetix	1.44 Mn	-4.50 Mn	4,303.00	-

Download Data